As an organ recipient, columnist Sam Kirton honors donors and their families each year by decorating holiday trees in the ...

Treatment with Endeavor Biomedicines’ experimental oral therapy ENV-101 (taladegib) improved lung function in people with IPF ...

Until then, my family chooses to remain thankful for the available PF treatments and hopeful about the advancements that are sure to come. A diagnosis of PF will change your life, but life is for the ...

Columnist Samuel Kirton attended the Pulmonary Fibrosis Foundation's Summit 2025, where the group's five-year strategic plan was unveiled.

This Veterans Day, columnist Samuel Kirton writes about the PACT Act, which expanded coverage for veterans exposed to toxic substances.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

BMS-986020 is an anti-fibrotic drug being developed by Bristol-Myers Squibb, and is chemically a lysophosphatidic acid (LPA) receptor antagonist. The drug, an oral formulation, is in clinical trials ...